Choice Points: Breast Cancer Treatment CD-ROM

乳腺癌将在美国妇女的一生中发生，大约八分之一的美国妇女将在1999年发生178，700例新病例。第二阶段SBIR将产生一个多媒体光盘，未来（Tm），这将有助于妇女作出知情的乳腺癌治疗决定。该产品将侧重于治疗的个人方面，使妇女有机会在治疗期间考虑非医疗需求，了解建议的治疗将如何影响她们的生活，并学习管理这些影响的方法。在第二阶段，我们将研究和制作剩余的信息内容和图形元素，同时为CD-ROM确定和开发额外的决策支持工具。完整的决策支持系统将包括有关乳腺癌、其治疗方法和这些治疗方法的影响的信息，以及用于更有效的信息处理、患者-提供者沟通、治疗相关问题解决、并澄清与治疗相关的偏好和价值观。产品在增加女性对其治疗决定的信心方面的有效性将在最近诊断为早期乳腺癌的女性中进行实地测试。拟议的商业应用：该产品具有商业潜力，可供制药公司用作增值患者教育，用于管理式护理组织的成员，以及作为单独销售给患者的消费品。

Breast cancer will strike approximately one in eight American women over their life span, with 178,700 new cases anticipated in 1999. This Phase II SBIR will result in a multimedia CD-ROM, Coming Out Ahead(Tm), that will help women make informed breast cancer treatment decisions. The product will focus on the personal aspects of the treatment, giving women an opportunity to consider non-medical needs during the treatment period, to learn how a suggested treatment will impact their lives, and to learn ways to manage these impacts. In Phase II, we will research and produce remaining informational content and graphic elements and concurrently identify and develop additional decision-support tools for the CD-ROM. The complete decision- support system will included information about breast cancer, its treatments, and the impact of those treatments, as well as tools for more effective information processing, patient-provider communication, treatment-related problem-solving, and clarification of treatment- related preferences and values. Product effectiveness in increasing women's confidence about their treatment decision will be field tested with recently diagnosed women with early-stage breast cancer. PROPOSED COMMERCIAL APPLICATIONS: This product has commercial potential for use by a pharmaceutical company as value-added patient education, for managed care organizations for their members, and as a consumer product sold individually to patients.